塞来昔布联合多柔比星（ADM）对人乳腺癌细胞MCF-7增殖的影响  

Effect of celecoxib and adriamycin on proliferation of breast cancer cell line MCF-7

作　　者：刘东[1] 李国宾[1] 刘万军[2] 

机构地区：[1]连云港市第二人民医院,连云港222023 [2]吉林大学第一临床医院乳腺外科,长春130000

出　　处：《中华内分泌外科杂志》2010年第1期13-16,共4页Chinese Journal of Endocrine Surgery

基　　金：江苏省连云港市2009年医学重点人才医药卫生科研课题（ZC317）

摘　　要：目的初步探讨塞来昔布联合多柔比星（ADM）对人乳腺癌细胞MCF-7的增殖和凋亡的影响，及其可能机制。方法用不同浓度的塞来昔布溶液、ADM溶液及二者联合用药（简称3药）分别与MCF-7细胞共育24h、48h、72h后，MTT法测定其对细胞的抑制作用。分别用3药作用MCF-7细胞48h后，流式细胞仪检测细胞周期和凋亡。结果10mg／L多柔比星、50μmol／L塞来昔布溶液分别与MCF-7细胞共育24h后，对MCF一7细胞的生长均有明显抑制作用（P〈0．01）。联合用药组的抑制作用更为显著。流式细胞术检测发现，给药细胞48h后，G0／G1期细胞比例升高，S期和G2／M期比例下降，3个给药组细胞均形成明显的凋亡峰，实验组各组与对照组的凋亡率差异有统计学意义（P〈0．01）。结论①塞来昔布和多柔比星均有抑制乳腺癌MCF-7细胞的作用，并呈时间和剂量依赖性；②塞来昔布能诱导MCF-7细胞凋亡，可能与阻止细胞周期进展有关；③塞来昔布与多柔比星联合应用可起到协同抗肿瘤的作用。Objective To study the roles of celecoxib and adriamycin in the inhibition of proliferation and the induction of apoptosis human breast cancer cells MCF-7. Methods MCF-7 cells together with celecoxib or/and adriamycin of different concentration after fostering 24,48,72 hours were carried out, the inhibition of pro- liferation was measured by MTF assay. Cell cycle and apoptotic percentage were analyzed by flow cytometry （FCM）. Results MCF-7 cells together with adriamycin （10mg/L） after fostering 24 hours were pressed down obviously（P 〈 0.01 ） , MCF-7 cells together with celecoxib （50μmol/L） after fostering 24 hours were pressed down obviously（ P 〈 0.01 ） , the effect was more obviously in the group of celecoxib combined and ADM. The flow cytometry shows that the proportion of G0/G1 phase and the apoptotic rate wee incresed significantly in all groups, the apoptotic rate was significant between all groups and control group（P 〈 0.01 ）. Conclusions The inhibition of celecoxib and adriamycin against human breast cancer MCF-7 is obviously with time dependence and dose dependence. Celecoxib can induce the apoptosis of human breast cancer MCF-7. Anti-tumor action of celecoxib combined and adriamycin against human breast cancer is cooperated.

关 键 词：塞来昔布 多柔比星 乳腺癌细胞 MTF法 细胞凋亡 

分 类 号：R737.9[医药卫生—肿瘤]